Publicaciones en colaboración con investigadores/as de Emory University (9)

2024

  1. Correction to: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (npj Breast Cancer, (2022), 8, 1, (98), 10.1038/s41523-022-00467-1)

    npj Breast Cancer

  2. Final Results from the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

    Journal of Clinical Oncology, Vol. 42, Núm. 15, pp. 1738-1744

  3. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

    European Journal of Cancer, Vol. 178, pp. 23-33

2022

  1. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139

  2. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

    npj Breast Cancer, Vol. 8, Núm. 1

  3. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

    npj Breast Cancer, Vol. 8, Núm. 1

2021

  1. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    Annals of Oncology, Vol. 32, Núm. 9, pp. 1148-1156

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1